Variables ultimately included in the acenocoumarol pharmacogenetic and clinical dosing algorithms, and values of Beta reflecting their relative weight in the final model.

<p>Beta: standardized regression coefficient, which reflects the relative weight of each variable included in the model.</p

Unadjusted R² for each group of variables and resultant cumulative R² of the final model.

<p>Unadjusted R² for each group of variables and resultant cumulative R² of the final model.</p

Percentage of global correct classification (Predicted Dose within ±20% of Real Dose) by genetic and clinical algorithms in the derivation, test and entire cohorts.

*<p>p<0.001</p

Precision expressed as MAE (SD) of pharmacogenetic and clinical algorithms by dose group in the entire cohort.

*<p>Between-group comparisons calculated by paired “t” test.</p

Characteristics of study cohorts.

(1)<p><i>CYP</i> inducers that were considered in this analysis included phenytoin, carbamazepine and rifampin.</p>(2)<p><i>CYP</i> inhibitors that were considered in this analysis included azoles, proton pump inhibitors and statins.</p>(3)<p>For <i>CYP2C9</i> genotype, the usual * designation is used (*2 = rs1799853 and *3 = rs1057910).</p>(4)<p>VV indicates homozygous V433 carriers; VM, heterozygous V433M carriers; MM, homozygous M433 carriers.</p

Comparison of R² and MAE in our study and two other studies (IWPC and EU-PACT).

<p>DC: Derivation cohort; EC: entire cohort; VC: Validation/Testing cohort; MAE: mean absolute error (mg/week). MAE for warfarin dose has been corrected considering a dose equivalence ratio of 0.57 between both drugs.</p

Patients correctly classified (predicted dose within ± 20% of the actual dosage) by genetic and clinical algorithms in the generation, validation and entire cohorts (n = 682).

<p>Patients correctly classified (predicted dose within ± 20% of the actual dosage) by genetic and clinical algorithms in the generation, validation and entire cohorts (n = 682).</p

Patients correctly classified (predicted dose within ± 20% of actual dosage) and MAE from the entire cohort (n = 682) by genetic and clinical algorithms according to dosage groups.

<p>Patients correctly classified (predicted dose within ± 20% of actual dosage) and MAE from the entire cohort (n = 682) by genetic and clinical algorithms according to dosage groups.</p

Patients characteristics in the generation (n = 556) and validation (n = 129) cohorts.

<p>Patients characteristics in the generation (n = 556) and validation (n = 129) cohorts.</p

Predictive performance of the pharmacogenetic algorithm by disease in the entire cohort (n = 682).

<p>Predictive performance of the pharmacogenetic algorithm by disease in the entire cohort (n = 682).</p